Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRMA 2
NCT00317915Phase 3Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of irbesartan in type 2 diabetes mellitus (T2DM), Microalbuminuria and hypertension (HTN) (3 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Time to development of overt nephropathy at 24 months. Status: completed.
02
Drugs
irbesartan
03
Conditions
type 2 diabetes mellitus (T2DM)Microalbuminuriahypertension (HTN)
Beyond the preview
Go deeper on NCT00317915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317915.